![Ruxolitinib phosphate Catalog No.:M10837-2 hexahydro-7-[[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]methylene]-4-(3](https://cdn.shopify.com/s/files/1/0389/1897/9723/products/M10837_1621562554.gif?v=1621562556)
Pay in 4 interest-free payments of $20.00 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
hexahydro-7-[[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]methylene]-4-(3
but local LY411575 administration promoted hearing recovery through transdifferentiation of supporting cells into hair cells after noise-induced hearing loss in the mature cochlea
and expression of α-SMA with concomitant suppression of cell growth in rat HSCs and human HSC-derived TWNT-4 cells
CAS Number: 1231930-82-7
Ruxolitinib phosphate Catalog No.:M10837-2 hexahydro-7-[[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]methylene]-4-(3Ruxolitinib, also known as INC424 and INCB18424 or INCB018424, is an orally bioavailable Janus associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK STAT (signal transducer and activator of transcription) pathway plays a key
US$ 727.50
US$ 104.75
US$ 349.00
US$ 1345.00
US$ 2802.50
US$ 186.50
US$ 1625.00